Clinical Trials in Pittsburgh

Showing 8461-8480 of 16,007 trials

Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients

NCT01417780

A study to evaluate the safety and pharmacokinetics profile of different doses of AB103 administered to patients diagnosed with Necrotizing Soft Tissue Infections that are scheduled for an urgent surgical intervention as part of their standard of care.

Necrotizing Soft Tissue Infections

Atox Bio Ltd43 participantsStarted Dec 2011

Los Angeles, California, United States • San Francisco, California, United States • Gainesville, Florida, United States +4 more locations

UNKNOWNPhase 3< 1 mile

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00651261

The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treatment alone. Midostaurin has been tested in over 400 patients and is being studied in a number of illnesses, including AML, colon cancer, and lung cancer. Midostaurin blocks an enzyme, produced by a gene known as FLT3, that may have a role in the survival and growth of AML cells. Not all leukemia cells will have the abnormal FLT3 gene. This study will focus only on patients with leukemia cells with the abnormal FLT3 gene.

Leukemia

Alliance for Clinical Trials in Oncology717 participantsStarted Apr 2008

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Sacramento, California, United States +173 more locations

Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Find Trials by Condition in Pittsburgh

CMX001 in Post-transplant Patients With BK Virus Viruria

COVID19 Neurological Manifestation

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Study of Octanorm Subcutaneous IG in Patients With PID

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma